Search Within

Tim Joseph Peterson

Formats
  1. Meeting Abstract (9)
  2. Journal Article (7)
  3. Review (2)
Groups
  1. Center for Hematologic Malignancies (14)
  2. Department of Medicine (14)
  3. Hematologic Malignancies, Division of (14)
  4. Epidemiology and Biostatistics (12)
  5. Survivorship Research (10)
  6. Biostatistics Service (8)

More Groups

People
  1. Alexander Lesokhin (8)
  2. Hani Hassoun (8)
  3. Malin Hultcrantz (8)
  4. Neha Korde (8)
  5. Sham Mailankody (8)
  6. Urvi Shah (8)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (4)
  4. 2020 (4)
  5. 2019 (4)
  6. 2018 (2)

More Years

Publications
  1. Blood (7)
  2. Annals of Pharmacotherapy (3)
  3. Clinical Lymphoma, Myeloma and Leukemia (2)
  4. British Journal of Haematology (1)
  5. Cancer (1)
  6. European Journal of Haematology (1)

More Publications

Publishers
  1. American Society of Hematology (7)
  2. John Wiley & Sons (3)
  3. Sage Publications (3)
  4. Elsevier Inc. (2)
  5. Wiley Blackwell (2)
  6. Elsevier Science, Inc. (1)

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib-lenalidomide-dexamethasone (KRD) with or without rivaroxaban prophylaxis
    Meeting Abstract

    Piedra, K. M.; Hassoun, H.; Buie, L. W.; Devlin, S. M.; Flynn, J.; Hultcrantz, M.; Lesokhin, A. M.; Lu, S. X.; Mailankody, S.; Shah, U. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • An observational, retrospective analysis of retreatment with carfilzomib in the management of patients with multiple myeloma
    Meeting Abstract

    Peterson, T. J.; Korde, N.; Hassoun, H.; Mailankody, S.; Lesokhin, A. M.; Hultcrantz, M.; Shah, U. A.; Smith, E. L.; Lu, S. X.; Landau, H. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Practice patterns with focal progression on daratumumab therapy
    Meeting Abstract

    Bal, S.; Peterson, T.; Landau, H.; Chung, D.; Giralt, S.; Korde, N.; Mailankody, S.; Smith, E.; Shah, U.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2019)

    Fulltext@MSK | Save
  • Current and investigational agents targeting the phosphoinositide 3-kinase pathway
    Journal Article

    Tang, L. A.; Dixon, B. N.; Maples, K. T.; Poppiti, K. M.; Peterson, T. J.
    Pharmacotherapy (2018)

    Fulltext@MSK | Save
  • Characteristics and outcomes of patients with hematologic malignancies receiving chemotherapy in the intensive care unit
    Journal Article

    Pastores, S. M.; Goldman, D. A.; Shaz, D. J.; Kostelecky, N.; Daley, R. J.; Peterson, T. J.; Tan, K. S.; Halpern, N. A.
    Cancer (2018)

    Fulltext@MSK | Save
  • Venetoclax: A first-in-class oral BCL-2 inhibitor for the management of lymphoid malignancies
    Journal Article

    King, A. C.; Peterson, T. J.; Horvat, T. Z.; Rodriguez, M.; Tang, L. A.
    Annals of Pharmacotherapy (2017)

    Fulltext@MSK | Save
  • Effects of obesity on the efficacy and toxicity of induction chemotherapy in adult acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Peterson, T. J.; Lin, A.; Hilden, P.; Devlin, S.; Adel, N. G.; Park, J. H.
    Blood (2015)

    Fulltext@MSK | Save